Intesa invests 360 million euros to manage its entire health insurance business

Published Date: 08 Mar 2023

Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.

Read Full News

Latest News

Germany Risks Missing Out on New Drugs, AstraZeneca CEO Says

AstraZeneca's CEO said Germany risks missing out on new drugs that ⁠the drugmaker plans to launch if the nation sticks with plans to keep pharmaceutical spending in check.

U.S. to Ask States to Revalidate "high-risk" Medicaid Providers

Mehmet Oz, who heads the agency that runs the U.S. Medicare and ⁠Medicaid healthcare programs, said on Tuesday the Trump administration plans to ask all ⁠50 states to...

US FDA Warns Medline Over Defective Heart Procedure Syringes

The U.S. Food and Drug Administration has told medical device maker Medline that its syringes used in heart procedures ⁠are defective and warned the company of penal actions.

Swiss Industry Body Says US Tariffs on Pharmaceuticals Will Harm Patients

U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, ⁠supply chains and ultimately will harm patients, Switzerland's...

The ACA Subsidy Gap and Its Toll on Primary Care

When the ACA’s subsidy credits expired at the end of 2025, physicians knew patient volume and overall revenue would tank. How are doctors faring?

Karyopharm's Drug Meets One Of Two Goals in Blood Cancer Trial

Karyopharm Therapeutics said on Tuesday its therapy led to significant reduction in spleen size in a late-stage ⁠study of patients with a rare blood cancer, meeting only one...

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

AstraZeneca's CEO said Germany risks missing out on new drugs that ⁠the drugmaker plans to launch if the nation sticks with plans to keep pharmaceutical spending in check.

Mehmet Oz, who heads the agency that runs the U.S. Medicare and ⁠Medicaid healthcare programs, said on Tuesday the Trump administration plans to ask all ⁠50 states to...

The U.S. Food and Drug Administration has told medical device maker Medline that its syringes used in heart procedures ⁠are defective and warned the company of penal actions.

U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, ⁠supply chains and ultimately will harm patients, Switzerland's...

When the ACA’s subsidy credits expired at the end of 2025, physicians knew patient volume and overall revenue would tank. How are doctors faring?

Karyopharm Therapeutics said on Tuesday its therapy led to significant reduction in spleen size in a late-stage ⁠study of patients with a rare blood cancer, meeting only one...

News All Time

AI tool creates digital twins of patients to predict their future health

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

New tool predicts graft failure after kidney transplant

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should help doctors predict which patients are most at risk of losing a transplanted kidney graft.

How are patients using health care chatbots? Study finds some 'eye-openers'

A health care chatbot can be a patient's first point of contact for some sensitive conversations from mental health to billing, a new CU Anschutz study has found.

A unified model of memory and perception: How Hebbian learning explains our recall of past events

A collaboration between SISSA's Physics and Neuroscience groups has taken a step forward in understanding how memories are stored and retrieved in the brain. The study, recently published in Neuron, shows that distinct perceptual ...

New study reveals high rates of fabricated and inaccurate citations in LLM-generated mental health research

A new study published in the journal JMIR Mental Health by JMIR Publications highlights a critical risk in the growing use of Large Language Models (LLMs) like GPT-4o by researchers: the frequent fabrication and inaccuracy ...

Would you put period blood on your face? What science says about 'menstrual masking'

In the ever-evolving world of beauty trends, few have sparked as much debate—and discomfort—as "menstrual masking." This is the practice of applying menstrual blood to the skin, usually the face, as a form of DIY skincare.

Simple test brings clarity and hope for families with inherited neuropathy

A new, inexpensive urine test that measures two sugar alcohols, sorbitol and xylitol, is making it easier, faster, and far less expensive to identify a common inherited nerve disorder called SORD-related neuropathy. The test, ...

Malaria rapid diagnostic test 'not fit for purpose,' international study claims

An international study published in the Malaria Journal claims that a widely used test for detecting malaria is delivering too many inaccurate false-negative results and is "not fit for purpose."

Reaching the unreachable: Endoscopy technique opens route to deep lung tumors

Researchers at the University of Osaka have engineered a novel technique, balloon-assisted bronchoscope delivery (BDBD), to guide endoscopes to small, early-stage lung cancers hidden deep within the periphery of the lungs.

Healing the heart after a heart attack with a biodegradable patch

A new patch developed by Texas A&M University researcher Dr. Ke Huang may offer a way to help the heart heal after a heart attack. The patch uses a unique microneedle system to deliver a therapeutic molecule directly to damaged ...

Ovarian tissue preservation enables future fertility for young woman with cancer

In patients of reproductive age who have cancer, fertility preservation for potential children in the future should be a high priority. A practice article published in the Canadian Medical Association Journal describes the ...

One of the world's oldest blood pressure drugs may also halt aggressive brain tumor growth

A Penn-led team has revealed how hydralazine, one of the world's oldest blood pressure drugs and a mainstay treatment for preeclampsia, works at the molecular level. In doing so, they made a surprising discovery—it can ...

From body fat to bone, experiment offers hope for 'gentle' repair of fractures

Japanese researchers are testing a surprising, minimally invasive way to repair spine fractures.

At some doctors' offices, AI is listening in the exam room

Bracken Babula starts patient visits these days by closing the exam room door and asking if they mind him recording their conversation. He hits a button on his mobile phone, checks that it is recording, and sits back in his ...

Software optimizes brain simulations, enabling them to complete complex cognitive tasks

A new software enables brain simulations which both imitate the processes in the brain in detail and can solve challenging cognitive tasks. The program was developed by a research team at the Cluster of Excellence "Machine ...

When life imitates art: Google searches for anxiety drug spike during run of The White Lotus TV show

In season three of the hit television series "The White Lotus," the character Victoria Ratliff takes the prescription anti-anxiety medication lorazepam to help with her social anxiety and inability to sleep. Her casual usage ...

Recommended News For You

The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.

The origin of BPH and prostate cancer in different prostate zones and the impact on the incidence of prostate cancer

Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.

LAIs vs Oral Antipsychotics for Bipolar I Rehospitalization

Chromatin organization linked to p53 tumor suppression mechanism

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

Recommended Articles For You

The Pros and Cons of Using Cyclophosphamide in Cancer Treatment  

Case Study: Artificial Intelligence in Early Cancer Detection 

Gut microbiota in curing cancer 

Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Sleep ALL night' program helps children with leukemia sleep better during treatment

2.

For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.

3.

Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer

4.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.

5.

EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer

1.

Ticagrelor Monotherapy vs. Ticagrelor + Aspirin in ACS Post-PCI: ULTIMATE-DAPT Trial

2.

Understanding Iron Saturation Levels in Your Blood 

3.

Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA

4.

The Benefits and Risks of Cervical Conization

5.

Unlocking the Mysteries of ICD 10 Code Normocytic Anemia

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

2.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

3.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

4.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

5.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot